Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 2 of 2 results for breast neoplasms

  1. Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence (TA810)

    Evidence-based recommendations on abemaciclib (Verzenios) with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence in adults.

    Technology appraisal guidance
    Published
    20 July 2022
    View recommendations

    Sections for TA810

  2. Fezolinetant for treating moderate to severe vasomotor symptoms associated with menopause (TA1143)

    Evidence-based recommendations on fezolinetant (Veoza) for treating moderate to severe vasomotor symptoms associated with menopause.

    Technology appraisal guidance
    Published
    31 March 2026

    Sections for TA1143